(February 2, 2017, 2:52 PM EST) -- WASHINGTON, D.C. — The federal government argues in a Jan. 24 opposition brief that the U.S. Supreme Court should not review a ruling that held Bayer Consumer Care AG (BCC) and Bayer Healthcare LLC (Bayer, collectively) could sue under Sections 14(3) and 43(a) of the Lanham Act over a foreign brand name the company never used in the United States because concerns that it would dramatically change U.S. trademark law were “overblown” (Belmora LLC and Jamie Belcastro v. Bayer Consumer Care AG, et al., No. 16-548, U.S. Sup.)....